Moreover, earlier studies marked that retained CD4+ and CD8+ T-cell responses were associated with reduced COVID-19 severity (44–46) and T-cell immunity to the SARS-CoV-2 may help to compensate the absence of neutralizing antibodies in preventing or limiting severe COVID-19 (33, 49). This evidence concerns the gene CD8A and COVID-19.